Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa.
Hirami Y, Mandai M, Sugita S, Maeda A, Maeda T, Yamamoto M, Uyama H, Yokota S, Fujihara M, Igeta M, Daimon T, Fujita K, Ito T, Shibatani N, Morinaga C, Hayama T, Nakamura A, Ueyama K, Ono K, Ohara H, Fujiwara M, Yamasaki S, Watari K, Bando K, Kawabe K, Ikeda A, Kimura T, Kuwahara A, Takahashi M, Kurimoto Y.
Cell Stem Cell. 2023 Dec 7;30(12):1585-1596.e6. doi: 10.1016/j.stem.2023.11.004.
Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review.
Bakthavatchalam M, Lai FHP, Rong SS, Ng DS, Brelen ME.
Surv Ophthalmol. 2018 May-Jun;63(3):329-339. doi: 10.1016/j.survophthal.2017.09.009. Epub 2017 Oct 5.
Protocol for the treatment of cystoid macular edema secondary to retinitis pigmentosa and other inherited retinal dystrophies.
Català-Mora J, Santamaría Álvarez JF, Kyriakou D, Alforja S, Barraso Rodrigo M, Blasco Palacio PB, Casaroli-Marano R, Cobos Martín E, Coco Martín RM, Esmerado C, García Tirado A, García P, Gómez-Benlloch A, Rodríguez Fernández CA, Vilaplana Mira F.
Arch Soc Esp Oftalmol (Engl Ed). 2024 Feb;99(2):67-81. doi: 10.1016/j.oftale.2023.11.001. Epub 2023 Nov 7.
Retinal vasoproliferative tumour secondary to retinitis pigmentosa sine pigmento.
Bromeo AJ, Lerit SJ, Veloso A, Mercado GJ.
BMJ Case Rep. 2021 May 19;14(5):e240878. doi: 10.1136/bcr-2020-240878.
Etiology of Retinitis Pigmentosa.
Breazzano MP, Grewal MR, Tsang SH, Chen RWS.
Methods Mol Biol. 2023;2560:15-30. doi: 10.1007/978-1-0716-2651-1_2.
CRB1-associated retinal degeneration is dependent on bacterial translocation from the gut.
Peng S, Li JJ, Song W, Li Y, Zeng L, Liang Q, Wen X, Shang H, Liu K, Peng P, Xue W, Zou B, Yang L, Liang J, Zhang Z, Guo S, Chen T, Li W, Jin M, Xing XB, Wan P, Liu C, Lin H, Wei H, Lee RWJ, Zhang F, Wei L.
Cell. 2024 Mar 14;187(6):1387-1401.e13. doi: 10.1016/j.cell.2024.01.040. Epub 2024 Feb 26.
Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR.
Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C, Nanda A, Davies A, Wood LJ, Salvetti AP, Fischer MD, Aylward JW, Barnard AR, Jolly JK, Luo E, Lujan BJ, Ong T, Girach A, Black GCM, Gregori NZ, Davis JL, Rosa PR, Lotery AJ, Lam BL, Stanga PE, MacLaren RE.
Nat Med. 2020 Mar;26(3):354-359. doi: 10.1038/s41591-020-0763-1. Epub 2020 Feb 24.
Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis Pigmentosa.
Michaelides M, Besirli CG, Yang Y, DE Guimaraes TAC, Wong SC, Huckfeldt RM, Comander JI, Sahel JA, Shah SM, Tee JJL, Kumaran N, Georgiadis A, Minnick P, Zeldin R, Naylor S, Xu J, Clark M, Anglade E, Wong P, Fleck PR, Fung A, Peluso C, Kalitzeos A, Georgiou M, Ripamonti C, Smith AJ, Ali RR, Forbes A, Bainbridge J.
Am J Ophthalmol. 2024 Nov;267:122-134. doi: 10.1016/j.ajo.2024.05.034. Epub 2024 Jun 12.
Tocilizumab for cystoid macular edema secondary to retinitis pigmentosa.
Abramowicz S, Kamgang Semeu P, Nubourgh I, Postelmans L, Willermain F.
J Ophthalmic Inflamm Infect. 2024 Sep 30;14(1):47. doi: 10.1186/s12348-024-00430-0.
Management of cystoid macular edema secondary to retinitis pigmentosa via subliminal micropulse yellow laser.
Arslan U.
Lasers Med Sci. 2021 Mar;36(2):317-323. doi: 10.1007/s10103-020-03031-0. Epub 2020 May 4.
